An in vitro apparatus was described in which miconazole formulated as commercial creams, pessaries and medicated tampons for intravaginal application could be assessed for its inhibitory action in vitro.
Introduction
Laboratory tests for antifungal sensitivities are usually restricted to determinations of the minimal inhibitory concentration (MIC) of pure antifungal substance for a given fungal isolate. The relationship between MIC and in vivo effectiveness of a given compound is not always clear, and in any case the commercial formulations of an antifungal that are used clinically are not, as a rule, tested in the laboratory. Antifungal MIC determinations are known to be affected by such performance variables as the composition of the culture medium (Hoeprich and Finn, 1972) , the presence or absence of serum proteins (Sreedhara Swamy, Sirsi and Ramonanda Rao, 1974) and the size of the test inoculum (Galgiani and Stevens, 1976 (Fig. 2) . As the concentration of amphotericin B increased, the culture turbidity remained essentially the same as that of an amphotericin-free control until at inhibitory concentrations of amphotericin B there was an abrupt fall in culture turbidity (Fig.  2a) . The change in culture turbidity with amphotericin B concentration occurred over 3 antifungal dilutions when turbidities were measured after 24 hr's incubation, and over 2 dilutions after 48 hr. By contrast, with flucytosine, the culture turbidity fell steadily from maximum (no inhibition) to minimum (full inhibition) over at least 4 tube dilutions (Fig. 2b) ; that is, partial inhibition was noted over a 16-fold range of flucytosine concentration. For miconazole, partially inhibitory effects were observed over a 128-fold range of concentration for all 3 strains (Fig. 2c) . The wide ranges of antifungal concentration over which partial inhibition was seen for flucytosine and miconazole rendered naked-eye determination of MIC highly liable to error.
In experiments where the inhibitory effects of the 3 test antifungals were assessed in terms of growth rate and cell yield of C. albicans ATCC 28366, it was observed that the effects of amphotericin B ranged from nil at 0.02 mg/l to fungicidal at 2-0 mg/l (Table 1) Table 3 show that all 3 miconazole vaginal formulations tested in the apparatus shown in Fig. 1 effectively inhibited varied enormously with the size of the test inoculum. Galgiani and Stevens (1976) recommended the routine use of turbidity measurements in antifungal MIC assays, since a 50% turbidity reduction figure proved to be more consistent and inoculumindependent than MIC. In view of the large range of concentration of miconazole and flucytosine over which partial inhibition of C. albicans was seen in the present study, it is clear that some objective, turbidity-based end-point is likely to be more reproducible from laboratory to laboratory; however, further experience with sensitivity tests will be required before such end-points may be related even circumstantially to the clinical efficacy of antifungal compounds. Inter-laboratory co-operation should, in time, lead to the introduction of a standard sensitivity test protocol for antifungal agents. The experiments with the vaginal model apparatus (Fig. 1, Table 3 ) provide a preliminary indication that commercial formulations of antifungal agents may be as amenable to laboratory investigation as pure antifungal compounds. The model has demonstrated that miconazole, in 3 different intravaginal formulations, is rapidly released, without impediment by protein binding, in concentrations sufficient to inhibit the growth of a surrounding C. albicans culture: this in vitro finding broadly correlates with in vivo results obtained in clinical trials of miconazole (Odds, 1977) .
